




www.worldfightcovid.com



STRATEGY FOR A CAMPAIGN OF EFFECTIVE VACCINATION

Since the start of the Covid-19 crisis, a vast outpouring of solidarity and generosity in place around the world to fight this pandemic. We took action concrete actions to help all countries face this difficult period in terms of prevention and vaccination. All countries have implemented a vaccination for their population. Different vaccines have been developed to combat this COVID 19. The cost of purchasing vaccines by governments is financially acceptable by a quantity minimal country.

The current policy is to vaccinate everyone. We do not wish to interfere in scientific and / or political decisions of each of the countries we work with currently.

We offer a simple strategy to implement place, unclog medical services identify asymptomatic and on counseling scientists bring approaching immunity the 100%.

WORLD FIGHT COVID



Urine test to test the immunity of populations
[98 % Efficiency]



1st injection
AstraZeneca



2nd injection
Sputnik V

97,70 %

RESULT

* Clinical studies are underway which could combining the two vaccines achieve a result of 97.70%



TEL: 32 486 86 68 37 - BELGIUM
WWW.STARGATEBCG.NET



MOKA 19



DR. Raymond F. Akers Jr.
AKERS NANOTECHNOLOGY

Rapid diagnostic tests and vaccinations against the novel SARS coronavirus-2 ("CoV-2") have been proposed as essential strategies to resolve the pandemic. Yet to date, the right combinations of these technologies have been elusive. **Akers Nanotechnology** offers here a new test solution associated with a new vaccination strategy which, according to it, will allow the pandemic to be brought under rapid control.

The available testing methods simply do not provide easy access to universal information about current infection or past exposure to CoV-2. PCR results, performed in the laboratory, take days or weeks to report and are entirely dependent on the nasal sampling technique. The accuracy of rapid antigen and antibody tests has strict limits on the days following symptoms. The difficulty of obtaining a nasal swab or a finger prick necessitates the reliable use of these tests in a clinical setting.

Akers Nanotechnology launches rapid urine test that will make the CoV-2 test universal. This test will identify people who have an active infection or who have been infected and who have antibodies that indicate protection against the virus. This two-step test is easily performed by anyone, anywhere, especially at home.

Since vaccine supply will not meet demand for the foreseeable future, this test will be essential to identify those who have already been exposed to CoV-2 and do not need immediate vaccination. Frequent testing will then indicate when the natural production of antibodies is no longer protective. Once identified, vaccination can take place. This way, the vaccine supply can be stretched and conserved for those who do not test positive for protective antibodies.

These strategies therefore combine instant testing information on CoV-2 antibodies with efficient vaccine use. **Akers Nanotechnology** is headquartered in New Jersey, USA and is a US FDA registered and New Jersey Department of Health and importer / exporter and facility and manufacturing facility and our medical storage platform in the US are located in Fort Myers, Florida. Our business partner is JTL Development & Investment worldwide.

We have two divisions: COVID-19 test products and vaccines, and nanotechnology diagnostic products.

COVID-19 test products include rapid antigen tests, based on saliva and nasal swabs, and rapid antibody tests, based on finger blood sample and urine COVID 19 antibody test.

The company's nanotechnology division designs and manufactures mobile health tests based on proprietary nanotechnologies and digital application platforms. These tests provide instant health and metabolism information and help make healthy lifestyle decisions. Products currently on the market relate to weight loss and fitness, Alzheimer's disease, high risk heart disease, and oxidative stress.

The company is currently developing a rapid 10-second breath test for CoV-2 based on its nanotechnology platforms that will store test results on a secure digital app on mobile devices.

Raymond F. Akers, Jr., Ph.D. has spent the past 35 years as an innovator in rapid diagnostic test products. He invented the company's products, as well as the products of his predecessors, and holds numerous patents and regulatory approvals. Mr. Akers has accompanied two companies in the IPO process, one on the NASDAQ and one on the London Stock Exchange's alternative investment market, and has successfully closed numerous secondary offers. He holds a doctorate. in Neuroscience from Northwestern University and a B.A. in Biology from Saint Joseph University.

DR. Raymond F. Akers Jr.



TEL: 32 486 86 68 37 - BELGIUM
WWW.STARGATEBCG.NET




MOKA 19

OUR STRATEGY : SWF COVID19

If clinical trials between the two vaccines are confirmed, our strategy would be based on the vaccination of populations who really need it and achieve 98% effective vaccination by combining the **AstraZeneca** vaccine first injection and second injection 21 days after the vaccine **Sputnik**.

This is to avoid vaccinating people who are already immune (asymptomatic and others) we have set up a campaign worldwide screening thanks to the urine test which can be carried out a few minutes at home without being a health worker.



URINE TEST



ASTRAZENECA



SPUTNIK

THE **ASYMPTOMATICS**

The term asymptomatic refers to the **absence of symptoms**. It may apply for an individual, a disease, or even a stage of a disease.

A symptom is a sign of illness, such as having a fever or cough. We could therefore think that asymptomatic patients are not sick: it is wrong. **An asymptomatic is a patient who ignores himself**. A asymptomatic person will therefore often be able to transmit a disease, even if she herself does not suffer the consequences. At least not right now ! Indeed, some diseases present a **long asymptomatic**, which delays its detection, before becoming symptomatic several years later.



THE FINDING

In each country the virus circulates and mutates towards a stronger contagion and more fast. The number of tests in each in each country is not sufficient to map in an instant who is carrier and who is not.

These tests are carried out only by health personnel, the number of healthcare workers are not scalable around the world to perform these tests.

The lead times for results are long, even the antigen test, which gives a result in 15 minutes cannot meet the needs of testing very quickly in large numbers of populations.

Problem of health personnel and supply of tests. The unknown problem : **The ASYMPTOMATICS** which represent a significant amount in the world.



THE REAL QUESTIONS

WHO IS A CARRIER WHO IS NOT?

CAN WE VACCINE ANYONE?

*- NO (THE VACCINE IS NOT COMPULSORY)
PROCEEDINGS ARE UNDERWAY TO DEFEND THIS RIGHT.*

DO WE HAVE ENOUGH STAFF TO TEST AND VACCINE 7,800,000,000 HUMAN BEINGS?

- NO

ARE WE IN A RACE AGAINST TIME?

- YES

CAN THE POPOPULATION OF EACH COUNTRY TEST ITSELF AND MEASURE ON IMMUNITY TO THE VIRUS?

- NOW YES

CAN ASYMPTOMATICS FROM ALL OVER THE WORLD BE IDENTIFIED?

- NOW YES

CAN COUNTRIES SPEND LESS ON BLIND VACCINATION?


- NOW YES

**WHY
NOW YES ?**



THE **ANSWER !**

SARS-COV-2 URINE ANTIBODY RAPID TEST



Available in two formats and always individually, the boxes and the strips, are THE ONLY AUTO Tests on the market to test WITHOUT BEING A HEALTHCARE PERSONNEL effectively your immunity, whether you are ASYMPTOMATIC or NON-ASYMPTOMATIC. This will give authorities an immediate map of people carrying the virus and determine their vaccination strategy.

Urine has previously been used to detect immunity to other viruses such as rubella, HIV2 and to assess vaccination against certain diseases. Although the concentration in physiological immunoglobulins is weak compared to that of blood, the patent of OLISACARE allows this biological medium to be used to establish people's immunity to SARS-CoV-2 Our Self-test will let you know if you have the antibodies to let you know if you are immune and not contagious.

The human, economic and social cost linked to COVID 19 prompts us to take all measures necessary to eradicate this scourge. Thanks to the complementary test vaccination, deconfinement is possible. If you are immune, you are not contagious, you can safely return to the normal course of your life while respecting all government precautionary measures.

The SARS-CoV-2 antibody test (lateral flow method) is an immunochromatographic test for the rapid and qualitative detection of the respiratory syndrome coronavirus 2 antibody severe acute (SARS-CoV-2) in a human urine sample. The test should be used for assist in the diagnosis of antibodies to infectious coronavirus disease (COVID-19), which is caused by SARS-CoV-2. The test provides preliminary results immediately (15 min).

HOME TEST WITHOUT A HEALTHCARE STAFF

The **OLISACARE COVID-19** Urine Test Device is an immunochromatographic assay kit for the rapid detection of immunoglobulin G (IgG) against COVID-19. This test is intended for use by the general population, people with suspicion of possible contamination with COVID-19, or having been vaccinated. The only recommendation who is to do the test with the "First urine of the morning, undiluted" should be scrupulously respected.



Morning urine only, undiluted, unfrozen.
Test to be performed within two hours of urine collection

WHY DO THIS TEST?

- ✓ Reassure people performing essential functions in high-risk environments or confined by offering them a reliable and rapid self-test, which can be carried out regularly in order to ensure their immunity.
- ✓ Accelerate progressive deconfinement in complete safety by allowing people to positive test, therefore immune and non-contagious, to circulate freely.
- ✓ Possibility of putting a QR code on the tests for the exit certificate to justify freedom of movement in the event of re-containment.
- ✓ Mass use for a census at time T of the past infection rate and present immunity of the population to refine forecasts, modulate the containment, and save on unnecessary tests and vaccines in case of immunity.
- ✓ Avoid additional costs for CPAMs already strongly impacted by the pandemic.



WHY DO THIS TEST?



AstraZeneca has developed with Oxford University a vaccine to be stored at 2 ° c. He responds to the numbers world health. AZD1222 uses chimpanzee viral vector deficient in replication based on a weakened version of a common cold virus (adenovirus) which causes infections in chimpanzees and contains the material SARS-CoV-2 virus spike protein genetics.

In participants who received two standard doses, vaccine efficacy was 62% (95% CI 41-75) in the ChAdOx1 vs 6% in the control group vaccinated with MenACWY.

In participants who received a low dose followed by standard dose, the efficacy was 90% (67% 4-97%).



Sputnik V is the world's first registered vaccine based on the human adenovirus vector platform well studied. It is currently among the top 10 vaccines close to the end of clinical trials and the launch of the mass production candidates on the Organization's list World Health Organization (WHO).

40,000 volunteers participate in the post-registration of Sputnik V in Russia.

Clinical trials of Sputnik V have been announced to United Arab Emirates, India, Venezuela and Belarus.

91.4% Sputnik V vaccine efficacy has been confirmed through data analysis at the final checkpoint of

clinical tests. The effectiveness of the Sputnik V vaccine against severe cases of coronavirus infection is 100%. The cost of an injection of the Sputnik V vaccine will be less than \$ 10 for foreign markets (the dose per person consists of two injections). The vaccine in lyophilized (dehydrated) form can be stored at a temperature of + 2 + 8 degrees Celsius.

More than 50 countries have placed purchase orders for more than 1.2 billion doses of Sputnik V vaccine.



If the combination of the two vaccines provides immunity against this virus up to 97.7%

Doing the urine test beforehand will provide effectiveness of the vaccination policy and will reassure people around the world.

The urine test and the two vaccines are sold separately.